Clinical Trial Update: A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) [Phase 1]

View source ↗

Summary

Phase 1, dose-escalation study of RP-A601 in PKP2 variant-mediated arrhythmogenic cardiomyopathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmogenic Cardiomyopathy

Drugs mentioned

• RP-A601

Snippet

Sponsor: Rocket Pharmaceuticals Inc. | Conditions: PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Phase 1 | Status: RECRUITING